Walvax BioTech receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Metrics to compare | 300142 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship300142PeersSector | |
|---|---|---|---|---|
P/E Ratio | 828.4x | 30.9x | −0.2x | |
PEG Ratio | −14.85 | 0.24 | 0.00 | |
Price/Book | 2.6x | 1.8x | 2.6x | |
Price / LTM Sales | 9.8x | 6.8x | 2.8x | |
Upside (Analyst Target) | −38.2% | 38.7% | 60.9% | |
Fair Value Upside | Unlock | 7.7% | 9.5% | Unlock |
Walvax Biotechnology Co., Ltd., engages in the research and development, manufacture, and distribution of vaccines in China and internationally. Its vaccine portfolio includes recombinant human papillomavirus bivalent, 13-valent pneumococcal polysaccharide conjugate, 23-valent pneumococcal polysaccharide, group ACYW135 meningococcal polysaccharide, group A and C meningococcal polysaccharide, group A and group C meningococcal conjugate, and haemophilus influenzae type b conjugate vaccines, as well as diphtheria, tetanus and acellular pertussis combined vaccine. The company was founded in 2001 and is headquartered in Kunming, China.